Detalhe da pesquisa
1.
Novel signatures associated with systemic lupus erythematosus clinical response to IFN-α/-ω inhibition.
Lupus
; 30(5): 795-806, 2021 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-33626969
2.
Human interferon-ϵ and interferon-κ exhibit low potency and low affinity for cell-surface IFNAR and the poxvirus antagonist B18R.
J Biol Chem
; 293(41): 16057-16068, 2018 10 12.
Artigo
Inglês
| MEDLINE | ID: mdl-30171073
3.
Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.
Lancet
; 392(10155): 1330-1339, 2018 10 13.
Artigo
Inglês
| MEDLINE | ID: mdl-30249507
4.
Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection.
Gastroenterology
; 150(7): 1568-1578, 2016 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-26946343
5.
Postoperative Complications after Ileocecal Resection in Crohn's Disease: A Prospective Study From the REMIND Group.
Am J Gastroenterol
; 112(2): 337-345, 2017 02.
Artigo
Inglês
| MEDLINE | ID: mdl-27958285
6.
Stability of lactate in venous blood gas and sodium fluoride-potassium oxalate plasma: a 6-year retrospective database analysis.
Clin Chem Lab Med
; 59(12): e438-e441, 2021 11 25.
Artigo
Inglês
| MEDLINE | ID: mdl-34291619
7.
WITHDRAWN: Experience with ustekinumab in patients with psoriasis enrolled in a large, multicenter, prospective, disease-based registry (Psoriasis Longitudinal Assessment and Registry [PSOLAR]).
J Am Acad Dermatol
; 2015 Jan 09.
Artigo
Inglês
| MEDLINE | ID: mdl-25582533
8.
Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
J Drugs Dermatol
; 14(7): 706-14, 2015 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-26151787
9.
Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies.
J Drugs Dermatol
; 13(12): 1441-8, 2014 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-25607786
10.
Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
J Drugs Dermatol
; 12(8): 874-80, 2013 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-23986160
11.
Non-linearity in lipase assays: A multicentric comparison on different analysers.
Clin Biochem
; 114: 63-66, 2023 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-36773631
12.
The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label study.
J Am Acad Dermatol
; 67(4): 642-50, 2012 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-22153792
13.
PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents.
J Drugs Dermatol
; 11(10): 1210-7, 2012 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-23134986
14.
Efficacy and Safety of Ustekinumab in Patients With Active Systemic Lupus Erythematosus: Results of a Phase II Open-label Extension Study.
J Rheumatol
; 49(4): 380-387, 2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-34853089
15.
[Myocardial injury in coronavirus disease 19 (Covid-19): main pathophysiological mechanisms and clinical utility of cardiac biomarkers]. / Atteintes myocardiques au cours de la maladie à coronavirus 19 (Covid-19) : principaux mécanismes physiopathologiques et utilité clinique des biomarqueurs cardiaques.
Ann Biol Clin (Paris)
; 79(3): 219-231, 2021 06 01.
Artigo
Francês
| MEDLINE | ID: mdl-34165431
16.
Suppression of Serum Interferon-γ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus Erythematosus.
Arthritis Rheumatol
; 73(3): 472-477, 2021 03.
Artigo
Inglês
| MEDLINE | ID: mdl-33010188
17.
Pharmacokinetics and Pharmacodynamics of JNJ-55920839, an Antibody Targeting Interferon α/ω, in Healthy Subjects and Subjects with Mild-to-Moderate Systemic Lupus Erythematosus.
Clin Drug Investig
; 40(12): 1127-1136, 2020 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-33085033
18.
Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase II Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus.
Arthritis Rheumatol
; 72(5): 761-768, 2020 05.
Artigo
Inglês
| MEDLINE | ID: mdl-31769212
19.
First-in-Human study of JNJ-55920839 in healthy volunteers and patients with systemic lupus erythematosus: a randomised placebo-controlled phase 1 trial.
Lancet Rheumatol
; 2(10): e613-e622, 2020 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-38273624
20.
Impact of Raltegravir or Efavirenz on Cell-Associated Human Immunodeficiency Virus-1 (HIV-1) Deoxyribonucleic Acid and Systemic Inflammation in HIV-1/Tuberculosis Coinfected Adults Initiating Antiretroviral Therapy.
Open Forum Infect Dis
; 7(2): ofz549, 2020 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-32083147